НАРУШЕНИЯ ОБМЕНА ГЛЮКОЗЫ У ПАЦИЕНТОВ, ПРИНИМАЮЩИХ ГЛЮКОКОРТИКОСТЕРОИДЫ: ОСОБЕННОСТИ КЛИНИЧЕСКИХ ПРОЯВЛЕНИЙ И КОРРЕКЦИИ

В обзоре рассматривается актуальная для специалистов различного профиля проблема нарушений углеводного обмена у пациентов, находящихся на кортикостероидной терапии. В статье подробно описываются эпидемиология и факторы риска развития нарушений углеводного обмена при применении глюкокортикостероидов. Приведены современные сведения об определении, распространенности, патогенезе стероид-индуцированной гипергликемии. Особое внимание уделено актуальным данным о вариантах нарушений углеводного обмена у пациентов терапевтического профиля. Подробно рассматриваются основные подходы к коррекции гликемии при стероид-индуцированных нарушениях углеводного обмена с помощью современной терапии.

Заключение. Широкое применение глюкокортикостероидов, значительная распространенность стероид-индуцированных нарушений углеводного обмена, особенности патогенетических механизмов стероид-индуцированного сахарного диабета обусловливают необходимость создания алгоритмов диагностики и лечения данных состояний. Сделан вывод, что рациональная сахароснижающая терапия, учитывающая патогенетические и клинические аспекты стероид-индуцированных нарушений углеводного обмена, может уменьшить скорость макро- и микрососудистых осложнений.

Конфликт интересов: авторы заявили об отсутствии конфликта интересов.

1. Diabetes Control and Complications Trial Research Group, Nathan D.M., Genuth S., Lachin J., Cleary P., Crofford O. et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993; 329(14): 977– 986. DOI: 10.1056/NEJM199309303291401

2. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131): 837–853.

3. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008; 358: 2560–2572. DOI: 10.1056/NEJMoa0802987

4. The FIELD study investigators. Effects of long-term fenofibrale therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366(9500): 1849–1861. DOI: 10.1016/S0140-6736(05)67667-2

5. Sjolie A.K., Porta M., Parving H.H. et al. The DIabetic REtinopathy Candersantan Trials (DIRECT) Programme: baseline characteristics. J. Renin Angiotensin Aldosterone Syst. 2005; 6(1): 25–32. DOI: 10.3317/jraas.2005.003

6. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016; 19(2): 104–112. DOI: 10.14341/DM2004116-17

7. Aryangat A.V., Gerich J.E. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vasc. Health Risk. Manag. 2010; 6: 145–155.

8. Kitasato L., Tojo T., Hatakeyama Y. et al. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on. Cardiovasc. Diabetol. 2012; 11: 79. DOI: 10.1186/1475-2840-11-79

9. Gordin D., Saraheimo M., Tuomikangas J. et al. Influence of postprandial hyperglycemic conditions on arterial stiffness in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2016; 101(3): 1134–1143. DOI: 10.1210/jc.2015-3635

10. Fong A.C., Cheung N.W. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res. Clin. Pract. 2013; 99(3): 277–280. DOI: 10.1016/j. diabres.2012.12.023

11. Uzu T., Harada T., Sakaguchi M. et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron. Clin. Pract. 2007; 105(2): 54–57. DOI: 10.1159/000097598

12. Miyawaki Y., Katsuyama T., Sada K.E. et al. A retrospective observational study of glucocorticoid-induced diabetes mellitus with IgA nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy. PLoS One. 2017; 12(5): e0178018. DOI: 10.1371/journal.pone.0178018

13. Dube S., Slama M.Q., Basu A. et al. Glucocorticoid excess increases hepatic 11β-HSD-1 activity in humans: implications in steroid-induced diabetes. J. Clin. Endocrinol. Metab. 2015; 100(11): 4155–4162. DOI: 10.1210/jc.2015-2673

14. Martínez B.B., Pereira A.C., Muzetti J.H. et al. Experimental model of glucocorticoid-induced insulin resistance. Acta. Cir. Bras. 2016; 31(10): 645–649. DOI: 10.1590/S0102-865020160100000001

15. Kim S.Y., Yoo C.G., Lee C.T. et al. Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J. Korean. Med. Sci. 2011; 26(2): 264–267. DOI: 10.3346/jkms.2011.26.2.264

16. Gulliford M.C., Charlton J., Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006; 29(12): 2728–2729. DOI: 10.2337/dc06-1499

17. Mills E., Devendra S. Steroid-induced hyperglycaemia in primary care. London J. Prim. Care (Abingdon). 2015; 7(5): 103–106. DOI: 10.1080/17571472.2015.1082344

18. Katsuyama T., Sada K.E., Namba S. et al. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res. Clin. Pract. 2015; 108(2): 273–279. DOI: 10.1016/j.diabres.2015.02.010

19. Gurwitz J.H., Bohn R.L., Glynn R.J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch. Intern. Med. 1994; 154(1): 97–101.

20. Shaharir S.S., Gafor A.H., Said M.S. et al. Steroidinduced diabetes mellitus in systemic lupus erythematosus patients: analysis from a Malaysian multi-ethnic lupus cohort. Int. J. Rheum. Dis. 2015; 18(5): 541–547. DOI: 10.1111/1756-185X.12474

21. Jeong Y., Han H.S., Lee H.D. et al. A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients. Cancer Res. Treat. 2016; 48(4): 1429–1437. DOI: 10.4143/crt.2015.464

22. Lee S.Y., Kurita N., Yokoyama Y. et al. Glucocorticoidinduced diabetes mellitus in patients with lymphoma treated with CHOP chemotherapy. Support Care Cancer. 2014; 22(5): 1385–1390. DOI: 10.1007/ s00520-013-2097-8

23. Sugiyama T., Sugimoto T., Suzuki S. et al. Current smoking is an independent risk factor for new-onset diabetes mellitus during highdose glucocorticoid treatment. Int. J. Clin. Pharmacol Ther. 2015; 53(8): 616–620. DOI: 10.5414/CP202136

24. Morita H., Oki Y., Ito T. Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM. Diabetes Care. 2001; 24(4): 788–789. DOI: 10.2337/diacare.24.4.788

25. Ogawa A., Johnson J.H., Ohneda M. et al. Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. J. Clin. Invest. 1992; 90(2): 497–504. DOI: 10.1172/JCI115886

26. Rebelato E., Santos L.R., Carpinelli A.R. et al. Shortterm high glucose culture potentiates pancreatic beta cell function. Sci Rep. 2018; 8(1): 13061. DOI: 10.1038/s41598-018-31325-5

27. Hauke S., Keutler K., Phapale P. et al. Endogenous fatty acids are essential signaling factors of pancreatic β-cells and insulin secretion. Diabetes. 2018; 67(10): 1986–1998. DOI: 10.2337/db17-1215

28. Hamamdzic D., Duzic E., Sherlock J.D. et al. Regulation of alpha 2-adrenergic receptor expression and signaling in pancreatic beta-cells. Am. J. Physiol. 1995; 269 (1 Pt 1): E162–171. DOI: 10.1152/ AJPENDO.1995.269.1.E162

29. Jacquement S., Briaud I., Rouault C. Longterm exposure of isolated rat islets to palitate inhibits insulin gene expression. Diabetes.1999; 48 (1058, Suppl 1): A 242.

30. Hagman D.K., Hays L.B., Parazzoli S.D. et al. Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans. J. Biol. Chem. 2005; 280(37): 32413–32418. DOI: 10.1074/ JBC.M506000200

31. Weinstein S.P., Wilson C.M., Pritsker A. et al. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism. 1998; 47(1): 3–6.

32. Monnier L., Colette C., Dunseath G.J., Owens D.R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007; 30(2): 263–269. DOI: 10.2337/dc06-1612

33. Burt M.G., Roberts G.W., Aguilar-Loza N.R. et al. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J. Clin. Endocrinol. Metab. 2011; 96(6): 1789–1796. DOI: 10.1210/jc.2010-2729

34. Otsuki M., Kitamura T., Tamada D. et al. Incompatibility between fasting and postprandial plasma glucose in patients with Cushing’s syndrome. Endocr. J. 2016; 63(11): 1017–1023. DOI: 10.1507/endocrj.EJ15-0748

35. De Micheli A. Corticosteroid induced diabetes mellitus: diagnosis and management. G. Ital. Nefrol. 2016 Malattie Metaboliche e Rene; 33(S68). pii: gin/33.S68.7

36. Burt M.G., Willenberg V.M., Petersons C.J. et al. Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology (Oxford). 2012; 51(6): 1112–1119.

37. Yanai H., Masui Y., Yoshikawa R. et al. Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes. World J. Diabetes. 2010; 1(3): 99–100. DOI: 10.4239/ wjd.v1.i3.99

38. Katsuyama H., Sako A., Adachi H. et al. Effects of 6-month sitagliptin treatment on metabolic parameters in diabetic patients taking oral glucocorticoids: a retrospective cohort study. J. Clin. Med. Res. 2015; 7(6): 479–484. DOI: 10.14740/jocmr2153w

39. Ghandour S., Azar S. Incretin based therapy in the management of steroid induced diabetes mellitus. Curr Diabetes Rev. 2014; 10(6): 360–363.

40. Ohashi N., Tsuji N., Naito Y. et al. Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels. Med. Sci. Monit. 2014; 20: 587–593. DOI: 10.12659/MSM.889872

41. Fransson L., Dos Santos C., Wolbert P. et al. Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome. Diabetol. Metab. Syndr. 2014; 6(1): 3. DOI: 10.1186/1758-5996-6-3

42. Vinodraj K., Nayak N. I.M., Rao J.V. et al. Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats. Indian J. Pharmacol. 2015; 47(2): 181–184. DOI: 10.4103/0253-7613.153426

43. Zhao R., Fuentes-Mattei E., Velazquez-Torres G. et al. Exenatide improves glucocorticoid-induced glucose intolerance in mice. Diabetes Metab. Syndr. Obes. 2011; 4: 61–65. DOI: 10.2147/DMSO.S15510

44. Tanaka M., Endo K., Suzuki T. et al. Treatment for steroid-induced diabetes with alpha-glucosidase inhibitor, voglibose. Eur. J. Neurol. 1998; 5(3): 315.

45. Ito S., Ogishima H., Kondo Y. Early diagnosis and treatment of steroid-induced diabetes mellitus in patients with rheumatoid arthritis and other connective tissue diseases. Mod. Rheumatol. 2014; 24(1): 52–59. DOI: 10.3109/14397595.2013.852855

46. Horasawa S., Osame K., Kawasumi K. et al. Efficacy of ipragliflozin in patients with steroid-induced hyperglycemia during cancer chemotherapy. Gan To Kagaku Ryoho. 2016; 43(5): 645–647 (In Japanese).

47. Willi S.M., Kennedy A., Brant B.P. et al. Effective use of thiazolidinediones for the treatment of glucocorticoidinduced diabetes. Diabetes Res. Clin. Pract. 2002; 58(2): 87–96.

48. Morita H., Oki Y., Ito T. et al. Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM. Diabetes Care. 2001; 24(4): 788–789. DOI: 10.2337/diacare.24.4.788

49. Spanakis E.K., Shah N., Malhotra K. et al. Insulin requirements in non-critically ill hospitalized patients with diabetes and steroid-induced hyperglycemia. Hosp. Pract. (1995). 2014; 42(2): 23–30. DOI: 10.3810/hp.2014.04.1100

50. Burt M.G., Drake S.M., Aguilar-Loza N.R. et al. Efficacy of a basal bolus insulin protocol to treat prednisolone-induced hyperglycaemia in hospitalised patients. Intern. Med. J. 2015; 45(3): 261–266. DOI: 10.1111/imj.12680